Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study.

ABSTRACT:

Background

Tocilizumab, a monoclonal antibody directed against the interleukin-6 receptor, has been proposed to mitigate the cytokine storm syndrome associated with severe COVID-19. We aimed to investigate the association between tocilizumab exposure and hospital-related mortality among patients requiring intensive care unit (ICU) support for COVID-19.

Methods

We did a retrospective observational cohort study at 13 hospitals within the Hackensack Meridian Health network (NJ, USA). We included patients (aged ≥18 years) with laboratory-confirmed COVID-19 who needed support in the ICU. We obtained data from a prospective observational database and compared outcomes in patients who received tocilizumab with those who did not. We applied a multivariable Cox model with propensity

SUBMITTER: Biran N 

PROVIDER: S-EPMC7428303 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature